Pacira Pharmaceuticals


Pacira Biosciences Clocks Preliminary Net Sales Of $118.7M In 1Q

Pacira Biosciences reported preliminary net product sales in 1Q FY21 of Exparel (bupivacaine liposome injectable suspension) and iovera of $114.7 million and $3.

Wedbush Raises Pacira Price Target Following Preannouncement Of 4Q14 EXPAREL Sales

In a research note issued today, Wedbush analyst Liana Moussatos (TipRanks #1) reiterated an Outperform rating on Pacira (NASDAQ:PCRX) and slightly raised her price …

Weakness In PCRX Following The FDA Warning Letter Is A Buying Opportunity, Says Wedbush

In a report issued today, analyst Liana Moussatos of Wedbush reiterated an Outperform rating on Pacira Pharmaceuticals (NASDAQ:PCRX) with a $117 price target, as the company recently announced …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts